Product Comparison


 

No Image

Strides Pharma 64380079701 Roche 00004080085 Genentech USA 50242087701 Genentech USA 50242086001
McKesson # 1218517 1121407 486348 1202342 1202317
Description Oseltamivir Phosphate 75 mg Capsule Blister Pack 10 Capsules Oseltamivir Phosphate 30 mg Capsule Blister Pack 10 Capsules Tamiflu® Oseltamivir Phosphate 75 mg Capsule Blister Pack 10 Capsules XOFLUZA™ Baloxavir Marboxil 80 mg Tablet Blister Pack 1 Tablet XOFLUZA™ Baloxavir Marboxil 40 mg Tablet Blister Pack 1 Tablet
Manufacturer # 3172206323164380079701000040800855024208770150242086001
Brand   Tamiflu®XOFLUZA™XOFLUZA™
Manufacturer Camber PharmaceuticalStrides PharmaRocheGenentech USAGenentech USA
Invoice OSELTAMIVIR PHOSPHATE, CAP 75MG UD (10/BX)OSELTAMIVIR PHOSPHATE, CAP 30MG UD (10/BX)TAMIFLU, CAP 75MG (10/PK)XOFLUZA, TAB 80MGXOFLUZA, TAB 40MG
    Log In to Order   Log In to Order   Log In to Order   Log In to Order   Log In to Order

Comparison

Alternate Manufacturer Number 39037703923125178731623458822345874
Country of Origin IndiaIndiaUnknownUnknownUnknown
Dosage Form CapsuleCapsuleCapsuleTabletTablet
Generic Drug Code 7344198980734414945945639
Generic Drug Name Oseltamivir PhosphateOseltamivir PhosphateOseltamivir PhosphateBaloxavir MarboxilBaloxavir Marboxil
NDC Number 3172206323164380079701000040800855024208770150242086001
Product Dating McKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 days
Quantity 10 Capsules10 Capsules10 Capsules1 Tablet1 Tablet
Strength 75 mg30 mg75 mg80 mg40 mg
Type Unit DoseUnit DoseGelcapUnit Dose
UNSPSC Code 5134180551341805513418055134330051343300
Application Flu Prevention and Treatment AgentFlu Prevention and Treatment AgentFlu Prevention and Treatment AgentFlu Prevention and Treatment AgentFlu Prevention and Treatment Agent
Container Type Blister PackBlister PackBlister PackBlister PackBlister Pack
Features and Benefits
  • XOFLUZA is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours